These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 33414133)

  • 1. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.
    Mehrvarz Sarshekeh A; Alshenaifi J; Roszik J; Manyam GC; Advani SM; Katkhuda R; Verma A; Lam M; Willis J; Shen JP; Morris J; Davis JS; Loree JM; Lee HM; Ajani JA; Maru DM; Overman MJ; Kopetz S
    Clin Cancer Res; 2021 Mar; 27(6):1663-1670. PubMed ID: 33414133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells.
    Kamori T; Oki E; Shimada Y; Hu Q; Hisamatsu Y; Ando K; Shimokawa M; Wakai T; Oda Y; Mori M
    Cancer Rep (Hoboken); 2022 Jan; 5(1):e1420. PubMed ID: 34042312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of ARID1A mutation on molecular characteristics in colorectal cancer.
    Tokunaga R; Xiu J; Goldberg RM; Philip PA; Seeber A; Battaglin F; Arai H; Lo JH; Naseem M; Puccini A; Berger MD; Soni S; Zhang W; Chen S; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
    Eur J Cancer; 2020 Nov; 140():119-129. PubMed ID: 33080474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.
    Marisa L; Svrcek M; Collura A; Becht E; Cervera P; Wanherdrick K; Buhard O; Goloudina A; Jonchère V; Selves J; Milano G; Guenot D; Cohen R; Colas C; Laurent-Puig P; Olschwang S; Lefèvre JH; Parc Y; Boige V; Lepage C; André T; Fléjou JF; Dérangère V; Ghiringhelli F; de Reynies A; Duval A
    J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection and Significance of Molecular Markers in Immunotherapy and Targeted Therapy of Colorectal Cancer in Tibet].
    Luo HH; Liu BY; Huo Z; BIANbazhaxi ; Wang Q; DUObula ; NImazhuoma ; DA Z; Wang H; Guo PP
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):184-192. PubMed ID: 38686714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Li L; Li M; Jiang Z; Wang X
    Cells; 2019 Jul; 8(7):. PubMed ID: 31277418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer.
    Hong JH; Cho HW; Ouh YT; Lee JK; Chun Y
    J Gynecol Oncol; 2023 Mar; 34(2):e18. PubMed ID: 36509464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer.
    Giordano G; Parcesepe P; D'Andrea MR; Coppola L; Di Raimo T; Remo A; Manfrin E; Fiorini C; Scarpa A; Amoreo CA; Conciatori F; Milella M; Caruso FP; Cerulo L; Porras A; Pancione M
    J Exp Clin Cancer Res; 2019 Jan; 38(1):28. PubMed ID: 30670049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and immune infiltration significance of ARID1A in TCGA molecular subtypes of gastric adenocarcinoma.
    Zhang Z; Li Q; Sun S; Ye J; Li Z; Cui Z; Liu Q; Zhang Y; Xiong S; Zhang S
    Cancer Med; 2023 Aug; 12(16):16716-16733. PubMed ID: 37366273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome.
    Fakih M; Ouyang C; Wang C; Tu TY; Gozo MC; Cho M; Sy M; Longmate JA; Lee PP
    J Clin Invest; 2019 Oct; 129(10):4464-4476. PubMed ID: 31524634
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Okamura R; Kato S; Lee S; Jimenez RE; Sicklick JK; Kurzrock R
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32111729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status.
    Ahtiainen M; Wirta EV; Kuopio T; Seppälä T; Rantala J; Mecklin JP; Böhm J
    Mod Pathol; 2019 Jun; 32(6):866-883. PubMed ID: 30723299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1.
    Sveen A; Johannessen B; Tengs T; Danielsen SA; Eilertsen IA; Lind GE; Berg KCG; Leithe E; Meza-Zepeda LA; Domingo E; Myklebost O; Kerr D; Tomlinson I; Nesbakken A; Skotheim RI; Lothe RA
    Genome Med; 2017 May; 9(1):46. PubMed ID: 28539123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application.
    Hu G; Tu W; Yang L; Peng G; Yang L
    Cancer Lett; 2020 Mar; 473():148-155. PubMed ID: 31911080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Infiltrating Lymphocytes and Macrophages Improve Survival in Microsatellite Unstable Colorectal Cancer.
    Narayanan S; Kawaguchi T; Peng X; Qi Q; Liu S; Yan L; Takabe K
    Sci Rep; 2019 Sep; 9(1):13455. PubMed ID: 31530839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
    Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
    Front Immunol; 2021; 12():798424. PubMed ID: 35145511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.